Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Surgery Partners (SGRY) Share Price
News headlines about Surgery Partners (NASDAQ:SGRY) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Surgery Partners earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2688626805933 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Surgery Partners, Inc. (SGRY) Downgraded by Zacks Investment Research to Strong Sell (americanbankingnews.com)
- Surgery Partners, Inc. (SGRY) Price Target Lowered to $17.00 at Citigroup Inc. (americanbankingnews.com)
- Surgery Partners, Inc. Expected to Earn Q3 2017 Earnings of $0.03 Per Share (NASDAQ:SGRY) (americanbankingnews.com)
- Surgery Partners Stock Plummets After Q2 Results Hint At Integration Challenges (finance.yahoo.com)
- Valeant Pharmaceuticals Stock Sweats Under Tax Spotlight; TRIP Tanks on Weak Forecast (schaeffersresearch.com)
Surgery Partners (SGRY) traded up 3.74% during trading on Friday, hitting $11.10. 844,033 shares of the company’s stock traded hands. Surgery Partners has a 12-month low of $9.20 and a 12-month high of $24.05. The firm’s 50-day moving average price is $20.32 and its 200 day moving average price is $20.21. The stock has a market cap of $541.80 million, a P/E ratio of 17.62 and a beta of 1.71.
Several research firms recently weighed in on SGRY. BidaskClub upgraded shares of Surgery Partners from a “hold” rating to a “buy” rating in a report on Wednesday, June 21st. Zacks Investment Research upgraded shares of Surgery Partners from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a research note on Wednesday, August 2nd. Raymond James Financial, Inc. restated a “market perform” rating on shares of Surgery Partners in a research note on Wednesday. Stifel Nicolaus downgraded shares of Surgery Partners from a “hold” rating to a “sell” rating and dropped their price target for the stock from $21.00 to $17.00 in a research note on Wednesday. Finally, Citigroup Inc. dropped their price target on shares of Surgery Partners from $28.00 to $17.00 and set a “buy” rating for the company in a research note on Friday. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $20.67.
WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Surgery Partners (SGRY) Share Price” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-surgery-partners-sgry-share-price.html.
About Surgery Partners
Surgery Partners, Inc is a healthcare services company. The Company operates in three lines of business across the United States: Surgical Facility Services, Ancillary Services and Optical Services. The Company’s Surgical Facility Services segment consists of the operation of ambulatory surgery centers (ASCs) and surgical hospitals, which include its anesthesia services.
Receive News & Ratings for Surgery Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surgery Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.